These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
156 related items for PubMed ID: 37689672
1. Treatment of idiopathic anaphylaxis with dupilumab: a case report. Pepper E, Pittman L. Allergy Asthma Clin Immunol; 2023 Sep 09; 19(1):82. PubMed ID: 37689672 [Abstract] [Full Text] [Related]
5. The management of exercise-induced anaphylaxis in a Chinese child with biologics: a case report. Jiang N, Xiang L, Huang H, Zhang X. Front Allergy; 2024 Nov 01; 5():1453873. PubMed ID: 39364293 [Abstract] [Full Text] [Related]
8. Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for Allergists. Gulen T, Akin C. Curr Allergy Asthma Rep; 2021 Feb 09; 21(2):11. PubMed ID: 33560495 [Abstract] [Full Text] [Related]
9. Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series. Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T. Ann Allergy Asthma Immunol; 2021 Oct 09; 127(4):481-487. PubMed ID: 34175498 [Abstract] [Full Text] [Related]
10. Emergency medical recognition and management of idiopathic anaphylaxis. Stoloff R, Adams SL, Orfan N, Harris KE, Greenberger PA, Patterson R. J Emerg Med; 1992 Oct 09; 10(6):693-8. PubMed ID: 1491151 [Abstract] [Full Text] [Related]
11. Idiopathic anaphylaxis: classification, evaluation, and treatment of 123 patients. Wiggins CA, Dykewicz MS, Patterson R. J Allergy Clin Immunol; 1988 Nov 09; 82(5 Pt 1):849-55. PubMed ID: 3192868 [Abstract] [Full Text] [Related]
12. Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab. Košnik M, Zugan L, Rijavec M. Int Arch Allergy Immunol; 2024 Nov 09; 185(8):761-766. PubMed ID: 38527445 [Abstract] [Full Text] [Related]
13. Management Strategies Of Idiopathic Anaphylaxis In The Emergency Room: Current Perspectives. Le M, Gabrielli S, De Schryver S, Ben-Shoshan M. Open Access Emerg Med; 2019 Nov 09; 11():249-263. PubMed ID: 31802955 [Abstract] [Full Text] [Related]
14. Clinical and functional differences among patients with idiopathic anaphylaxis. Tejedor Alonso MA, Sastre Dominguez J, Sánchez-Hernández JJ, PérezFrances C, Hoz de la Caballer B. J Investig Allergol Clin Immunol; 2004 Nov 09; 14(3):177-86. PubMed ID: 15552710 [Abstract] [Full Text] [Related]
15. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. Demirtürk M, Gelincik A, Colakoğlu B, Dal M, Büyüköztürk S. J Dermatol; 2012 Jun 09; 39(6):552-4. PubMed ID: 22390871 [Abstract] [Full Text] [Related]
16. [Idiopathic anaphylaxis]. Moneret-Vautrin DA. Eur Ann Allergy Clin Immunol; 2004 Jan 09; 36(1):13-9. PubMed ID: 15015747 [Abstract] [Full Text] [Related]
17. Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab. Puxkandl V, Hoetzenecker W, Altrichter S. Allergol Select; 2023 Jan 09; 7():17-19. PubMed ID: 36644012 [Abstract] [Full Text] [Related]
18. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. Carter MC, Maric I, Brittain EH, Bai Y, Lumbard K, Bolan H, Cantave D, Scott LM, Metcalfe DD. J Allergy Clin Immunol; 2021 Mar 09; 147(3):1004-1010.e2. PubMed ID: 33220353 [Abstract] [Full Text] [Related]
19. Successful management of chronic urticaria and food allergies in a pediatric population using integrative traditional Chinese medicine therapy: a case series. Fan X, McKnight T, Neshiwat J, Park S, Chung D, Li XM. Clin Mol Allergy; 2022 Nov 25; 20(1):12. PubMed ID: 36434719 [Abstract] [Full Text] [Related]
20. Corticosteroid-dependent idiopathic anaphylaxis: a report of five cases. Wiggins CA, Dykewicz MS, Patterson R. J Allergy Clin Immunol; 1989 Sep 25; 84(3):311-5. PubMed ID: 2778237 [Abstract] [Full Text] [Related] Page: [Next] [New Search]